At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 114 enrolled
Drug / intervention
Pioglitazone +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-Week, Open Label, Phase IV Trial to Evaluate the Efficacy of Pioglitazone 30 mg in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy of Metformin, Sulfonylurea, and Pioglitazone 15 Mg (ADD Trial)
In Brief
A Phase 4 clinical trial evaluating Pioglitazone, Metformin, and 1 other intervention for Type II Diabetes Mellitus. Completed, enrolled 114 participants across 9 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy of pioglitazone 30 mg on glycemic control when used in participants with inadequately controlled type 2 diabetes mellitus treated with stable combinations of metformin and sulfonylurea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II Diabetes Mellitus
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartDec 2013
Primary CompletionOct 2016
TodayJul 2026
First PostedOct 30, 2013
Enrollment StartDec 16, 2013
Primary CompletionOct 17, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.7 years ago
Interventions
Pioglitazonedrug
Pioglitazone tablets
Metformindrug
Metformin as prescribed in clinical practice
Sulfonylureadrug
Sulfonylurea as prescribed in clinical practice